- 6 updates
GlaxoSmithKline has been fined £297 million and its former country manager handed a suspended prison sentence in China for bribery.
GSK accepted the decision by the Changsha Intermediate People's Court in Hunan province that it had bribed doctors and hospitals to use its products, adding it has taken steps to change its working practices.
ITV News China Correspondent Lucy Watson reports from Beijing:
Mark Reilly, the former China head of British drugmaker GlaxoSmithKline, will be deported from China and will not face jail time in the country, Reuters has reported citing a source with direct knowledge of the matter.
"Reilly will be deported so he won't be in detention in China," said the source with knowledge of the matter who declined to be named because of the sensitivity of the case.
A fine of £297 million for drug giant GlaxoSmithKline has not worried investors, with shares in GSK rising 0.8%, or 11p, to £14.47 in morning trading in London.
GlaxoSmithKline said a bribery case in China had been a "deeply disappointing matter" after a number of company executives were jailed and the firm was fined £297 million.
GSK said in a statement on their website that the activities by the firm's China unit were a "clear breach" of GSK's governance and compliance procedures.
GSK Chief Executive Officer Sir Andrew Witty said:
Former GlaxoSmithKline China chief Mark Reilly and other GSK executives will be jailed for two to four years for paying out bribes, state news agency Xinhua said.
China has fined British pharmaceuticals giant three billion yuan (£297 million) in what is a record penalty for China, Xinhua said.
China has fined British drug firm GlaxoSmithKline $492 million and jailed company executives on bribery charges, the Associated Press has reported.